http://researchonline.federation.edu.au/vital/access/manager/Index ${session.getAttribute("locale")} 5 http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:14837 Wed 25 Nov 2020 10:04:34 AEDT ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:13780 0.1). The depressor response to pentolinium was greater in BPH/2J than BPN/3J, but in both cases the response in RD mice was similar to sham. Enalaprilat decreased MAP more in RD BPH/2J compared to sham (−12 vs −3 mmHg, P < 0.001) but had no effect in BPN/3J. RD reduced renal noradrenaline in both strains but more so in BPH/2J. RD reduced renin mRNA and protein, but not plasma renin in BPH/2J to levels comparable with BPN/3J mice. We conclude that renal nerves contribute to hypertension in BPH mice as RD induced a sustained fall in MAP, which was associated with a reduction of intrarenal renin expression. The lack of inhibition of the depressor effects of pentolinium and enalaprilat by RD suggests that vasoconstrictor effects of the SNS or RAS are not involved.]]> Wed 07 Apr 2021 14:01:53 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:13727 Wed 07 Apr 2021 14:01:50 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:13721 Wed 07 Apr 2021 14:01:49 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:13538 Wed 07 Apr 2021 14:01:40 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:12775 Wed 07 Apr 2021 14:00:59 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:11958 Wed 07 Apr 2021 13:57:15 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:11679 Wed 07 Apr 2021 13:56:58 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:10772 Wed 07 Apr 2021 13:56:08 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:10751 Wed 07 Apr 2021 13:56:06 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:10451 Wed 07 Apr 2021 13:55:49 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:10351 Wed 07 Apr 2021 13:55:42 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:10127 Wed 07 Apr 2021 13:55:26 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:9618 Wed 07 Apr 2021 13:54:52 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:7662 Wed 07 Apr 2021 13:47:08 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:7624 Wed 07 Apr 2021 13:47:06 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:7301 Wed 07 Apr 2021 13:46:46 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:7300 Wed 07 Apr 2021 13:46:46 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:7283 Wed 07 Apr 2021 13:46:45 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:7284 Wed 07 Apr 2021 13:46:45 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:7288 Wed 07 Apr 2021 13:46:45 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:7282 Wed 07 Apr 2021 13:46:45 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:7286 Wed 07 Apr 2021 13:46:45 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:7285 Wed 07 Apr 2021 13:46:45 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:7167 Wed 07 Apr 2021 13:46:40 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:7166 G–MspI or rs1800544; −262 G>A–HhaI or rs1800544; 1780 C>T–DraI or rs553668) in 403 adult patients with ADHD assessed in relation to comorbidity and personality characteristics, as well as in 232 controls. The diagnosis followed DSM-IV criteria, and personality dimensions were evaluated with the Temperament and Character Inventory (TCI). There were no significant differences in allele and genotype frequencies between cases and controls. Patients carrying the G allele of rs1800544 presented lower scores in harm avoidance, and carriers of the T allele of rs553668 had more novelty seeking and less harm avoidance and persistence. Additionally, the haplotype carrying the G-G-T alleles (rs1800544–rs1800545–rs553668) was associated with lower scores in harm avoidance and persistence, and higher scores in novelty seeking compared to other haplotypes. These findings suggest that the conflicting findings obtained in association studies between ADRA2A polymorphisms and ADHD might be related to temperament profiles, and support additional studies addressing these effects in larger samples.]]> Wed 07 Apr 2021 13:46:40 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:7163 T; Int8 VNTR and 3-VNTR), and their possible role in therapeutic response to MPH treatment in a sample of 171 Brazilian adults with ADHD. The diagnostic procedures followed the DSM-IV criteria and the outcome measures were the scales Swanson, Nolan, and Pelham Rating scale version IV and the Clinical Global Impression-Severity Scale, applied at the beginning and after the 30th day of treatment. Drug response was assessed by both categorical and dimensional approaches. There was no effect of any DAT1 polymorphisms or haplotypes on MPH response. This is the second report demonstrating absence of differences in MPH response according to DAT1 genotypes in adults with ADHD. Although DAT protein is crucial for the effect of MPH, genetic variations in DAT1 gene probably do not have a significant clinical role in this sample of adults with ADHD. © 2009 Springer-Verlag.]]> Wed 07 Apr 2021 13:46:40 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:7193 Wed 07 Apr 2021 13:46:40 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:7161 Wed 07 Apr 2021 13:46:39 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:6926 Wed 07 Apr 2021 13:46:28 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:6459 Wed 07 Apr 2021 13:46:03 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:5804 Wed 07 Apr 2021 13:45:22 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:5741 Wed 07 Apr 2021 13:45:18 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:5378 Wed 07 Apr 2021 13:45:01 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:5379 Wed 07 Apr 2021 13:45:01 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:5261 Wed 07 Apr 2021 13:44:54 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:5126 Wed 07 Apr 2021 13:44:45 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:4861 Wed 07 Apr 2021 13:44:25 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:4790 1.1) were differentially expressed between HHR and NHR (n=16). We then performed an in silico analysis to predict the miRNAs that are able to bind to the 3′ untranslated region of Endog mRNA, and therefore could regulate Endog levels. We discovered that the miRNAs let-7b, miR-338 and miR-347 are predicted to bind to Endog mRNA. Functional studies are being undertaken to determine whether these miRNAs can regulate Endog mRNA levels in vitro and their role in the pathological processes leading to cardiac hypertrophy. These miRNAs could be a new target for the prevention and treatment of cardiac hypertrophy in humans]]> Wed 07 Apr 2021 13:44:20 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:4560 Wed 07 Apr 2021 13:44:02 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:17011 Tue 20 Dec 2022 15:35:27 AEDT ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:7287 Tue 01 Mar 2022 09:44:30 AEDT ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:14433 Thu 19 May 2022 12:14:45 AEST ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:18750 140 mmHg and/or diastolic blood pressure (DBP) at least 90 mmHg (International Society of Hypertension guidelines), affects over 1.5 billion people worldwide. Hypertension is associated with increased risk of cardiovascular disease (CVD) events (e.g. coronary heart disease, heart failure and stroke) and death. An international panel of experts convened by the International Society of Hypertension College of Experts compiled lifestyle management recommendations as first-line strategy to prevent and control hypertension in adulthood. We also recommend that lifestyle changes be continued even when blood pressure-lowering medications are prescribed. Specific recommendations based on literature evidence are summarized with advice to start these measures early in life, including maintaining a healthy body weight, increased levels of different types of physical activity, healthy eating and drinking, avoidance and cessation of smoking and alcohol use, management of stress and sleep levels. We also discuss the relevance of specific approaches including consumption of sodium, potassium, sugar, fibre, coffee, tea, intermittent fasting as well as integrated strategies to implement these recommendations using, for example, behaviour change-related technologies and digital tools. **Please note that there are multiple authors for this article therefore only the name of the first 30 including Federation University Australia affiliates “Fadi Charchar, Priscilla Prestes, Britt Klein, Colette Browning, Olutope Akinnibosun and Shane Thomas” are provided in this record**]]> Thu 18 Jan 2024 11:16:43 AEDT ]]> http://researchonline.federation.edu.au/vital/access/manager/Repository/vital:15041 Mon 17 May 2021 13:30:30 AEST ]]>